RealFeedApp CTEV passed Phase 2a clinical trial in ten adult patients
Humacyte launched a Phase 2a clinical study of its coronary tissue-engineered vessel, CTEV, in ten patients undergoing bypass surgery. The FDA approved the investigational new drug application in July 2026, with patency assessed at two months and follow-up up to three years.
- Field
- medicine and diagnostics
- What they did
- Humacyte has started a Phase 2a clinical trial of its tissue-engineered vessel, CTEV, in ten patients undergoing coronary artery bypass grafting.
- Why it matters
- The study aims to evaluate the safety and efficacy of CTEV as a vascular conduit that is designed to be repopulated by the patient's own cells.
#clinical trial#tissue engineering#coronary artery#fda approval
